Robert Bonwetsch, MD
Neurology · Danbury, CTNPI 1801856687
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,784 and has fallen 98.8% since, to $21 in 2024.
Across 124 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$284
- Novartis$278
- Acadia Pharmaceuticals Inc$134
- Lundbeck LLC$125
- Supernus Pharmaceuticals, Inc.$116
- Eisai Inc.$111
- plus $1K from 32 others
Across 20 payments — averaging $12,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$223K
- AbbVie$20K
- Amgen$0
What the payments were for
- Food & beverage$2,256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 13 | $284 |
| Novartis | 15 | $278 |
| Acadia Pharmaceuticals Inc | 12 | $134 |
| Lundbeck LLC | 7 | $125 |
| Supernus Pharmaceuticals, Inc. | 7 | $116 |
| Eisai Inc. | 5 | $111 |
| Sanofi | 5 | $104 |
| Boston Scientific | 1 | $92 |
| Biogen | 4 | $78 |
| Grifols USA, LLC | 4 | $74 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| EMD Serono, Inc. | 4 | $57 |
| GE HealthCare | 3 | $53 |
| AbbVie(2 entities) | 3 | $51 |
| CSL Behring | 2 | $49 |
| Greenwich Biosciences, Inc. | 2 | $48 |
| Portola Pharmaceuticals, LLC | 3 | $45 |
| Livanova USA, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $43 |
| Shire North American Group Inc | 2 | $40 |
| AstraZeneca | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| SK Life Science, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Promius Pharma LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Amgen | 1 | $11 |
How this compares
$2,256 in reported general payments places this provider in the 60th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 36 | $306,560 |
| KeppraLevetiracetam | 49 | $90,067 |
| LamictalLamotrigine | 36 | $66,354 |
| TopamaxTopiramate | 15 | $66,286 |
| MysolinePrimidone | 24 | $62,873 |
| BriviactBrivaracetam | 28 | $56,623 |
| Lamictal XrLamotrigine | 24 | $50,958 |
| OnfiClobazam | 27 | $50,094 |
| Rufinamide | 17 | $40,187 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $38,068 |
| MyrbetriqMirabegron | 76 | $38,015 |
| QuliptaAtogepant | 17 | $24,941 |
| VimpatLacosamide | 16 | $24,207 |
| EpidiolexCannabidiol (Cbd) | 13 | $21,968 |
| Carbamazepine ErCarbamazepine | 106 | $20,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat | $284 | $80,83044 claims |
| Lundbeck LLCOnfi | $125 | $50,09427 claims |
| AbbVieQulipta, Linzess | $51 | $38,39640 claims |
| Eisai Inc.Fycompa | $111 | $19,50715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 280 neurology providers in Connecticut.
Other neurology in Danbury
- David GrecoDanbury$34K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.